Respirology : official journal of the Asian Pacific Society of Respirology
-
Randomized Controlled Trial Multicenter Study
Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial.
Studies in respiratory diseases other than chronic obstructive pulmonary disease suggest potentially differing responses to medications among patients from different regions. We report a subgroup analysis of patients recruited to Asian centres from a previously reported 4-year COPD trial. ⋯ In COPD patients from Asia, tiotropium improves lung function, improves health-related quality of life and reduces exacerbations over 4 years of treatment.
-
Randomized Controlled Trial Multicenter Study
An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis.
We evaluated the efficacy and safety of everolimus, a macrocyclic proliferation signal inhibitor with anti-fibroproliferative activity to prevent disease progression or death in patients with IPF, a progressive, fatal disease with no known effective therapy. ⋯ Everolimus use was associated with more rapid disease progression in a well-defined cohort of patients with IPF confirmed by surgical lung biopsy followed for 3 years.
-
Randomized Controlled Trial Multicenter Study
Sleep hypoventilation due to increased nocturnal oxygen flow in hypercapnic COPD patients.
This study shows the risks and benefits of increasing the nocturnal oxygen flow in hypercapnic COPD patients undergoing LTOT, as recommended by some COPD treatment guidelines to avoid nocturnal desaturation. ⋯ The increase of oxygen flow in severe COPD patients with established daytime hypercapnia improved nocturnal oxygenation but it also led to greater hypercapnia and respiratory acidosis at awakening in a considerable proportion of these patients.
-
Randomized Controlled Trial Multicenter Study
Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
The efficacy and safety of the anti-IgE antibody, omalizumab, has been widely studied in patients with asthma. However to date, no large studies have been performed in Asian populations. The aim of this study was to compare the efficacy and safety of omalizumab with placebo, as add-on therapy in Asian patients with moderate-to-severe persistent asthma. ⋯ Add-on treatment with omalizumab improved asthma control without significant adverse events in Japanese patients with moderate-to-severe persistent asthma.
-
Randomized Controlled Trial Multicenter Study
Varenicline for smoking cessation: a placebo-controlled, randomized study.
Varenicline tartrate, a novel, selective, nicotinic acetylcholine receptor partial agonist, has been developed specifically as a smoking cessation drug. This study evaluated the efficacy of a standard regimen of varenicline compared with placebo for smoking cessation in 333 subjects in China, Singapore and Thailand. ⋯ Varenicline was significantly more efficacious for smoking cessation than placebo over a 12-week treatment period and a further 12-week non-treatment follow-up period in smokers from China, Singapore and Thailand. No significant side-effects were noted.